3D-QSAR and docking studies of pentacycloundecylamines at the sigma-1 (σ1) receptor

Simple item page
dc.contributor.authorGeldenhuys, Werner J.
dc.contributor.authorNovotny, Nicholas
dc.contributor.authorMalan, Sarel F.
dc.contributor.authorVan der Schyf, Cornelis J.
dc.date.accessioned2018-01-10T09:54:07Z
dc.date.available2018-01-10T09:54:07Z
dc.date.issued2013
dc.description.abstractPentacycloundecylamine (PCU) derived compounds have been shown to be promising lead structures for the development of novel drug candidates aimed at a variety of neurodegenerative and psychiatric diseases. Here we show for the first time a 3D quantitative structure–activity relationship (3D-QSAR) for a series of aza-PCU-derived compounds with activity at the sigma-1 (r1) receptor. A comparative molecular field analysis (CoMFA) model was developed with a partial least squares cross validated (q2) regression value of 0.6, and a non-cross validatedr2 of 0.9. The CoMFA model was effective at predicting the sigma-1 activities of atest set with an r2 >0.7. We also describe here the docking of the PCU-derivedcompounds into a homology model of the sigma-1 (r1) receptor, which was developed to gain insight into binding of these cage compounds to the receptor. Based on docking studies we evaluated in a [3H]pentazocine binding assay anoxa-PCU, NGP1-01 (IC50 = 1.78 lM) and its phenethyl derivative (IC50 = 1.54 lM). Results from these studies can be used to develop new compounds with specific affinity for the sigma-1(r1)en_US
dc.description.accreditationWeb of Science
dc.identifier.citationGeldenhuys, W.J. et al. (2013). 3D-QSAR and docking studies of pentacycloundecylamines at the sigma-1 (σ1) receptor. Bioorganic & Medicinal Chemistry Letters, 23: 1707 – 1711en_US
dc.identifier.issn0968-0896
dc.identifier.urihttp://dx.doi.org/10.1016/j.bmcl.2013.01.069
dc.identifier.urihttp://hdl.handle.net/10566/3370
dc.language.isoenen_US
dc.privacy.showsubmitterFALSE
dc.publisherElsevieren_US
dc.rightsThis is the author-version of the article published online at: http://dx.doi.org/10.1016/j.bmcl.2013.01.069
dc.status.ispeerreviewedTRUE
dc.subjectPentacycloundecylaminesen_US
dc.subjectSigma-1 receptoren_US
dc.subjectCoMFAen_US
dc.subjectGlaucomatous neurodegenerationen_US
dc.subjectHomology modelingen_US
dc.title3D-QSAR and docking studies of pentacycloundecylamines at the sigma-1 (σ1) receptoren_US
dc.typeArticleen_US

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Geldenhuys_3D-QSAR-and-docking_2013.pdf
Size:
1.44 MB
Format:
Adobe Portable Document Format
Description:
Download

Collections

Research Articles (School of Pharmacy)